{"id":"virazole","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNINGS USE OF AEROSOLIZED VIRAZOLE IN PATIENTS REQUIRING MECHANICAL VENTILATOR ASSISTANCE SHOULD BE UNDERTAKEN ONLY BY PHYSICIANS AND SUPPORT STAFF FAMILIAR WITH THE SPECIFIC VENTILATOR BEING USED AND THIS MODE OF ADMINISTRATION OF THE DRUG. STRICT ATTENTION MUST BE PAID TO PROCEDURES THAT HAVE BEEN SHOWN TO MINIMIZE THE ACCUMULATION OF DRUG PRECIPITATE, WHICH CAN RESULT IN MECHANICAL VENTILATOR DYSFUNCTION AND ASSOCIATED INCREASED PULMONARY PRESSURES (SEE WARNINGS ). SUDDEN DETERIORATION OF R"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Chest soreness","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Conjunctivitis","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Death","drugRate":"10%","severity":"serious"},{"effect":"Bronchospasm","drugRate":"","severity":"serious"},{"effect":"Pulmonary edema","drugRate":"","severity":"serious"},{"effect":"Cardiac arrest","drugRate":"","severity":"serious"},{"effect":"Pneumothorax","drugRate":"","severity":"serious"},{"effect":"Apnea","drugRate":"","severity":"serious"},{"effect":"Hemolytic anemia","drugRate":"","severity":"serious"},{"effect":"Hypotension","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Ventilator dependence","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["IV Ribavirin"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"adf16e64-345f-469a-b987-3fbdd17e0ac2","title":"VIRAZOLE (RIBAVIRIN) POWDER, FOR SOLUTION [BAUSCH HEALTH US, LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T02:57:02.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07419373","phase":"PHASE2","title":"ARN-75039 Lassa Fever Treatment in West Africa","status":"RECRUITING","sponsor":"Arisan Therapeutics, Inc.","startDate":"2026-02","conditions":"Lassa Fever","enrollment":135},{"nctId":"NCT06212336","phase":"PHASE2, PHASE3","title":"ISTH/ANRS 0409s INTEGRATE Lassa Fever Study","status":"RECRUITING","sponsor":"Irrua Specialist Teaching Hospital","startDate":"2025-05-02","conditions":"Lassa Fever","enrollment":1755},{"nctId":"NCT01466192","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":108},{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C(CHC)","enrollment":74},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":109},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01753557","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C (CHC)","enrollment":54},{"nctId":"NCT01468584","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-11","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT04356677","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2","status":"WITHDRAWN","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-05","conditions":"COVID19","enrollment":""},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT00199719","phase":"PHASE2","title":"Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2003-06","conditions":"Chronic Hepatitis C","enrollment":30},{"nctId":"NCT01309490","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients","status":"TERMINATED","sponsor":"Jewish General Hospital","startDate":"2011-03-17","conditions":"Malignant Solid Tumor","enrollment":5},{"nctId":"NCT02940496","phase":"PHASE2","title":"Pembrolizumab (MK-3475) in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection","enrollment":15},{"nctId":"NCT06488300","phase":"PHASE2","title":"Assessing Antiviral Treatments in Early Symptomatic RSV","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-25","conditions":"Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human","enrollment":1000},{"nctId":"NCT06922643","phase":"PHASE4","title":"Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2011-03-01","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02483260","phase":"NA","title":"Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever","status":"ENROLLING_BY_INVITATION","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2016-06-16","conditions":"Viral Hemorrhagic Fever","enrollment":30},{"nctId":"NCT00623168","phase":"PHASE2","title":"Ribavirin for Hemorrhagic Fever With Renal Syndrome","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2008-02","conditions":"Hemorrhagic Fever With Renal Syndrome","enrollment":""},{"nctId":"NCT06744777","phase":"PHASE3","title":"The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-17","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Severe Dengue","enrollment":284},{"nctId":"NCT04283513","phase":"PHASE2","title":"Treatment of Hemorrhagic Fever With Ribavirin","status":"ACTIVE_NOT_RECRUITING","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-10-31","conditions":"Hemorrhagic Fever","enrollment":50},{"nctId":"NCT02890719","phase":"PHASE3","title":"Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.","status":"WITHDRAWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2016-08-03","conditions":"Liver Transplantation, Hepatitis C","enrollment":""},{"nctId":"NCT01194037","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2011-06-23","conditions":"Chronic Hepatitis C Infection, Genotype 1","enrollment":30},{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT00866021","phase":"PHASE4","title":"Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-02","conditions":"HIV/HCV Co-infection, HIV Infections","enrollment":68},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT06860334","phase":"PHASE2","title":"UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-07-01","conditions":"Crimean-Congo Hemorrhagic Fever","enrollment":378},{"nctId":"NCT06222723","phase":"PHASE2","title":"LAssa Fever Adjunct Treatment With DEXamethasone","status":"RECRUITING","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2024-02-05","conditions":"Lassa Fever","enrollment":42},{"nctId":"NCT03655561","phase":"","title":"Lassa Fever Clinical Course and Prognostic Factors in Nigeria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for International Medical Action","startDate":"2018-04-05","conditions":"Lassa Fever, Lassa Virus Infection, Pregnancy Complications","enrollment":1200},{"nctId":"NCT04048850","phase":"","title":"Zepatier in Patients with Substance Use","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-09-20","conditions":"Hepatitis C, Hiv, Coinfection, HIV","enrollment":25},{"nctId":"NCT02259855","phase":"PHASE1","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-01","conditions":"Hepatic Insufficiency","enrollment":36},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT01634919","phase":"","title":"Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin","status":"COMPLETED","sponsor":"Seoul National University Boramae Hospital","startDate":"2012-07","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT02460133","phase":"PHASE4","title":"Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2015-07-10","conditions":"Hepatitis C Virus","enrollment":44},{"nctId":"NCT00835146","phase":"PHASE1","title":"Ribavirin 200 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-09","conditions":"Healthy","enrollment":28},{"nctId":"NCT00835536","phase":"PHASE1","title":"Ribavirin 200 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-09","conditions":"Healthy","enrollment":27},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT05940545","phase":"PHASE1, PHASE2","title":"UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2023-07-12","conditions":"CCHF","enrollment":24},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT01056523","phase":"PHASE1, PHASE2","title":"Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2010-01","conditions":"Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT01268579","phase":"NA","title":"Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-12-28","conditions":"HEAD & NECK Cancer","enrollment":9},{"nctId":"NCT02073838","phase":"PHASE2","title":"Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML","status":"COMPLETED","sponsor":"Sarit Assouline","startDate":"2015-05","conditions":"Acute Myeloid Leukemia","enrollment":23},{"nctId":"NCT04664010","phase":"NA","title":"Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19)","status":"COMPLETED","sponsor":"Xi'an International Medical Center Hospital","startDate":"2020-02-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT06034691","phase":"NA","title":"Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-09-10","conditions":"Hemodialysis Access Failure","enrollment":40},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT01700179","phase":"PHASE1","title":"Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Chronic Hepatitis C Infection","enrollment":8},{"nctId":"NCT01849562","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2013-04","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT00571714","phase":"NA","title":"Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-04-01","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02340962","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2015-05","conditions":"Hepatitis C, Chronic","enrollment":25},{"nctId":"NCT02743897","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-05-01","conditions":"End Stage Renal Disease","enrollment":62},{"nctId":"NCT01866930","phase":"PHASE3","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07-11","conditions":"Chronic Hepatitis C Infection","enrollment":453},{"nctId":"NCT03067129","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-20","conditions":"Hepatitis C Virus (HCV)","enrollment":129},{"nctId":"NCT03797066","phase":"PHASE4","title":"ATTIC - Access To Treat in the Community","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2019-03-23","conditions":"Hepatitis C, Chronic","enrollment":13},{"nctId":"NCT03702218","phase":"EARLY_PHASE1","title":"Hepatitis C Positive Donor Into Hepatitis C Negative Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":1596},{"nctId":"NCT04653818","phase":"PHASE4","title":"HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-10-05","conditions":"Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence","enrollment":84},{"nctId":"NCT01439776","phase":"PHASE4","title":"Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients","status":"COMPLETED","sponsor":"Hanyang University","startDate":"2011-09","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT04907682","phase":"PHASE2","title":"Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever","status":"COMPLETED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2021-07-30","conditions":"Lassa Fever","enrollment":40},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT03144440","phase":"","title":"Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-13","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT02087111","phase":"PHASE4","title":"Telaprevir in Genotype 3 HCV","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-04","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02308241","phase":"NA","title":"Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-02","conditions":"Human Papillomavirus (HPV)-Related Malignancies, Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies","enrollment":12},{"nctId":"NCT00559091","phase":"PHASE2","title":"A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2007-04","conditions":"Acute Myelocytic Leukemia","enrollment":18},{"nctId":"NCT00062816","phase":"PHASE1, PHASE2","title":"Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2003-06","conditions":"Hepatitis C, Chronic","enrollment":22},{"nctId":"NCT05532306","phase":"PHASE1","title":"Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition","status":"COMPLETED","sponsor":"Future University in Egypt","startDate":"2020-10-11","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT04774107","phase":"PHASE1","title":"The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2020-11-26","conditions":"Hepatitis C, Chronic","enrollment":17},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT02634008","phase":"PHASE3","title":"Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-06","conditions":"Hepatitis C, Acute","enrollment":83},{"nctId":"NCT03760666","phase":"PHASE1, PHASE2","title":"A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Clear Creek Bio, Inc.","startDate":"2018-12-20","conditions":"Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT01058512","phase":"PHASE2","title":"A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy","status":"COMPLETED","sponsor":"Cellectar Biosciences, Inc.","startDate":"2010-03","conditions":"Hepatitis C","enrollment":22},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":615},{"nctId":"NCT04563208","phase":"PHASE2","title":"Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-09","conditions":"Covid19, SARS-CoV Infection","enrollment":80},{"nctId":"NCT03889106","phase":"","title":"Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2019-03-01","conditions":"Lassa Fever","enrollment":2},{"nctId":"NCT02109744","phase":"PHASE1, PHASE2","title":"Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-03","conditions":"Acute Myelogenous Leukemia","enrollment":27},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04605588","phase":"PHASE2","title":"A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-12-02","conditions":"SARS-CoV Infection, Covid19","enrollment":7},{"nctId":"NCT02939989","phase":"PHASE3","title":"Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-11-21","conditions":"Hepatitis C Virus Infection","enrollment":33},{"nctId":"NCT01192698","phase":"NA","title":"Intravenous Interferon During Liver Transplant","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-10","conditions":"Hepatitis C, Cirrhosis","enrollment":15},{"nctId":"NCT01380938","phase":"PHASE3","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2018-12-01","conditions":"Chronic Hepatitis","enrollment":1150},{"nctId":"NCT05229510","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-03-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT03365635","phase":"PHASE4","title":"Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-09-22","conditions":"Hepatitis C, Hemodialysis, Nosocomial Infection","enrollment":6},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT03146741","phase":"PHASE1, PHASE2","title":"Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-05-16","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT00078403","phase":"PHASE2","title":"Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections, Hepatitis C, Liver Disease","enrollment":333},{"nctId":"NCT02946034","phase":"PHASE4","title":"Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-02-01","conditions":"Chronic Kidney Disease, Chronic Hepatitis C","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"19940926","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19930304","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19930401","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19890313","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19851231","type":"ORIG","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19890328","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19880915","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19890602","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19860827","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19980326","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19900606","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"20140627","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19940310","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19890313","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19930712","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19920923","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19870409","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19930205","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"20000228","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"19860827","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"},{"date":"20160106","type":"SUPPL","sponsor":"BAUSCH","applicationNumber":"NDA018859"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":98,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Virazole","genericName":"Virazole","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}